Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Sheba Medical Center |
---|---|
Information provided by: | Sheba Medical Center |
ClinicalTrials.gov Identifier: | NCT00449592 |
Zinc is an intracellular mineral with important enzymatic cofactor activities for cell membrane stability, DNA and RNA structure. Zinc deficiency is associated with delayed wound healing and immune dysfunction. In patietns with hematological malignancies an inverse correlation was found between disease stage and zinc level. Patients undergoing high dose chemotherapy for hematologic malignancies are predisposed to develop oral and gastrointestinal complications, in particular oral mucositis. These patients may have relative zinc deficiency, therefore oral zinc therapy may be benefical in the prevention of these complications.
Condition | Intervention | Phase |
---|---|---|
Mucositis |
Drug: Zinc Drug: Placebo |
Phase IV |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | A Ramdomized Double Blined Placebo Controlled Oral Zinc Therapy for the Prevention of Mucositis in Patients Undergoing High Dose Chemotherapy With Stem Cell Support |
Estimated Enrollment: | 40 |
Study Start Date: | April 2007 |
Study Completion Date: | September 2008 |
Primary Completion Date: | September 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Oral zinc therapy, intervention
|
Drug: Zinc
Oral Zincol 1 Tab TID from day -6/-7 until discharge
|
2: Placebo Comparator
oral placebo
|
Drug: Placebo
Oral placebo 1 Tab TID from day -6/-7 until discharge
|
Patients candidate for High dose chemotherapy with stem cell support for the diagnosis of relapsed/resistant Hodgkins or NHL or MM will be screened for enrollment in the study.
Patients will be randomized in a 1:1 ratio to therapy with either zincol 1 Tab TID or placebo 1 Tab TID.
Therapy will start on the morning before commencing chemotherapy and will continue untill the first of either discharge day or day 21.
Response assesment will include:
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Israel | |
Division of Hematology and Bone Marrow Transplantation, Sheba Medical Center | |
Ramat-Gan, Israel |
Principal Investigator: | Maya Koren-Michowitz, MD | Sheba Medical Center |
Responsible Party: | Sheba Medical Center ( Dr. Maya Koren-Michovitz ) |
Study ID Numbers: | SHEBA-06-4196-MKM-CTIL |
Study First Received: | March 18, 2007 |
Last Updated: | October 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00449592 |
Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Stem cell transplantation Mucositis Zinc |
Mouth Diseases Digestive System Diseases Mucositis Gastrointestinal Diseases |
Zinc Stomatognathic Diseases Gastroenteritis |
Growth Substances Physiological Effects of Drugs Trace Elements Micronutrients Pharmacologic Actions |